Personalized maintenance therapy: a smarter way to treat advanced cancer?

NCT ID NCT02029001

Recruiting now Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase II trial is testing whether continuing targeted therapy or immunotherapy based on a tumor's molecular profile can benefit patients with advanced solid tumors that have stopped responding to prior treatment. After an initial treatment period, patients whose disease is stable or improved are randomly assigned to either continue or stop the therapy. The goal is to see if maintenance treatment can delay progression and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: targeted therapies (nilotinib, everolimus, and others) and immunotherapy (durvalumab + tremelimumab) selected based on tumor molecular profile
What this could lead to: If successful, this approach could help identify which patients with advanced solid tumors benefit from continuing targeted therapy or immunotherapy after initial disease control, potentially improving outcomes without unnecessary treatment.
What could go wrong: This is an early-phase trial with many different tumor types and drugs, so results may not apply broadly. Side effects from the therapies are possible, and the benefit of maintenance treatment remains unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT CENTRAL NERVOUS SYSTEM TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer central nervous system cancer metastatic neoplasm neoplasm Neoplasm Metastasis neoplasm with perivascular epithelioid cell differentiation tenosynovial giant cell tumor, diffuse type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID NEOPLASMS

Contacts and locations

Locations

Centre Hospitalier Lyon Sud
RECRUITING

Lyon, 69495, France
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Hôpitaux Universitaires de Strasbourg
RECRUITING

Strasbourg, France
Institut Bergonié
RECRUITING

Bordeaux, 33076, France
Institut Claudius Regaud
RECRUITING

Toulouse, 31059, France
Institut Curie
RECRUITING

Paris, 75248, France
Institut Paoli Calmettes
RECRUITING

Marseille, 13273, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.